Literature DB >> 17894531

In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.

Yu Zhang1, Kyle Gilbertson, Warren H Finlay.   

Abstract

In vitro polydisperse aerosol deposition in three mouth-throat models, namely, the USP (United States Pharmacopeia) mouth-throat (induction port), idealized mouth-throat, and highly idealized mouth-throat, was investigated experimentally. Aerosol particles emitted from two commercial inhalers, Qvar (pMDI) and Turbuhaler (DPI), were used. The in vitro deposition results in these three mouth-throat models were compared with in vivo data available from the literature. For the DPI, mouth-throat deposition was 57.3 +/- 4.5% for the USP mouth-throat, 67.8 +/- 2.2% for the idealized mouth-throat, and 69.3 +/- 1.1% for the highly idealized mouth-throat, which are all relatively close to the in vivo value of 65.8 +/- 10.1%. In contrast, for the pMDI, aerosol deposition in the idealized mouth-throat (25.8 +/- 4.2%) and the highly idealized mouth-throat (24.9 +/- 2.8%) agrees with the in vivo data (29.0 +/- 18.0%) reported in the literature better than that for the USP mouth-throat (12.2 +/- 2.7%). In both cases, the USP mouth-throat gives the lowest deposition among the three mouth-throat models studied. In summary, both the idealized mouth-throat and highly idealized mouth-throat improve the accuracy of predicted mean in vivo deposition in the mouth-throat region. This result hints at the potential applicability of either the idealized mouth-throat or highly idealized mouth-throat as a future USP mouth-throat standard to provide mean value prediction of in vivo mouth-throat deposition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17894531     DOI: 10.1089/jam.2007.0584

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  27 in total

1.  Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.

Authors:  Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2010-05-08       Impact factor: 4.200

2.  Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?

Authors:  Patricia Tang; Philip Chi Lip Kwok; Zhenbo Tong; Runyu Yang; Judy Agnes Raper; Hak-Kim Chan
Journal:  Pharm Res       Date:  2012-02-11       Impact factor: 4.200

3.  Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: comparison of CFD predictions with experimental results.

Authors:  P Worth Longest; Michael Hindle
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

4.  Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler.

Authors:  Rajoshi Biswas; Nicola A Hanania; Ashutosh Sabharwal
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-02-03       Impact factor: 2.849

5.  The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease.

Authors:  Dave Singh; Arjun Ravi; Katie Kane; Tess Schmalbach; David L Hava
Journal:  Br J Clin Pharmacol       Date:  2018-07-10       Impact factor: 4.335

6.  Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles.

Authors:  Yue Zhou; Jaijie Sun; Yung-Sung Cheng
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-07-06       Impact factor: 2.849

7.  De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.

Authors:  Sharon Shui Yee Leung; Patricia Tang; Qi Tony Zhou; Zhenbo Tong; Cassandra Leung; Janwit Decharaksa; Runyu Yang; Hak-Kim Chan
Journal:  AAPS J       Date:  2015-07-23       Impact factor: 4.009

Review 8.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

9.  Targeting aerosol deposition to and within the lung airways using excipient enhanced growth.

Authors:  Geng Tian; P Worth Longest; Xiang Li; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-01-03       Impact factor: 2.849

10.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.